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Twelve new Cyclophostin and Cyclipostins analogs (CyC19-30) were synthesized, thus extending our 
series to 38 CyCs. Their antibacterial activities were evaluated against four pathogenic mycobacteria 
(Mycobacterium abscessus, Mycobacterium marinum, Mycobacterium bovis BCG and 
Mycobacterium tuberculosis) and two Gram negative bacteria. The CyCs displayed very low toxicity 
towards host cells and were only active against mycobacteria. Importantly, several CyCs were active 
against extracellular M. abscessus (CyC17/CyC18β/CyC25/CyC26) or intramacrophage residing 
mycobacteria (CyC7(α,β)/CyC8(α,β)) with minimal inhibitory concentrations (MIC50) values 
comparable to or better than those of amikacin or imipenem, respectively. An activity-based protein 
profiling combined with mass spectrometry allowed identification of the potential target enzymes of 
CyC17/CyC26, mostly being involved in lipid metabolism and/or in cell wall biosynthesis. Overall, 
these results strengthen the selective activity of the CyCs against mycobacteria, including the most 
drug-resistant M. abscessus, through the cumulative inhibition of a large number of Ser- and Cys-
enzymes participating in key physiological processes. 
 
 
Keywords: Total synthesis; drug susceptibility; activity based-protein profiling; proteomics analysis. 
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Produced by Streptomyces species,1 natural Cyclophostin (CyC1 – Figure 1) is characterized 
by a unique seven-membered cyclic phosphate triester fused to a butyrolactone ring. This bicyclic 
core also contains a unique enol phosphate and chiral centers at both phosphorus and C-3a carbon 
atom. The structurally related natural Cyclipostins (e.g., Cyclipostin P CyC18 - Figure 1), which 
varied in the nature of the lipophilic chain attached to the phosphate, were described as bacterial 
growth inhibitors of various mycobacteria.2 Together, compelling evidence suggests the great 
potential for cyclic enolphosphate and phosphonate analogs of Cyclophostin (and the Cyclipostins) 
as anti-mycobacterial agents.  
To explore this hypothesis, we have reported the synthesis of Cyclipostins and Cyclophostin 
analogs (namely the CyCs – Figure 1).3-6 We first demonstrated that this first series of 26 CyCs 
(Figure 1) was able to efficiently inhibit the growth of Mycobacterium tuberculosis H37Rv, in vitro 
as well as in infected macrophages, with very low toxicity towards the host cells.7 These studies also 
strongly support the assumption that CyC compounds are multi-target inhibitors impairing various 
mycobacterial Ser- or Cys-containing enzymes involved in important physiological processes via the 
formation of a covalent bond between the enol-phosphorous atom and the catalytic residue.4-5, 7-9 The 
efficiency/selectivity of these CyCs was investigated further towards three slow-growing species 
(i.e., M. marinum, M. bovis BCG, and M. tuberculosis) and various mycobacterial clinical isolates 
and bacteria responsible for nosocomial infections, including Gram-negative and Gram-positive 
bacteria as well as rapidly-growing mycobacteria (RGM) belonging to the Mycobacterium chelonae-
abscessus clade.10 Remarkably, the inhibitory activity of these CyCs was exclusively restricted to 
mycobacteria.10 Notably, the most potent inhibitor (CyC17) exhibited minimal inhibitory 
concentrations (MIC) values comparable to those of most classical antibiotics used to treat M. 
tuberculosis and M. abscessus infections.7, 10 Collectively, these results emphasized the attractiveness 
of this new family of compounds as valid drug candidates to be exploited in future therapeutic 
developments against mycobacterial-associated infections, especially against M. abscessus the most 
drug-resistant mycobacterial species.10 
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Figure 1. Chemical structure of natural Cyclipostins and Cyclophostin, and related CyC analogs. Natural 
Cyclophostin (CyC1), Cyclipostin P (CyC18β) and its trans diastereoisomer (CyC18α), Cyclophostin 
phosphonate analog (CyC2), monocyclic enolphosphorus analogs to either Cyclophostin (CyC3-10;15-16) or 
Cyclipostins (CyC11-14;17). CyC6-10 and CyC13 were obtained as two diastereoisomers, being either in a trans 
(α-isomer) or cis (β-isomer) conformation between the OMe on the phosphorus and the H-substituent on the 
C-5 carbon atom. Adapted from 7. 
 
Over the last decade, non-tuberculous mycobacterial (NTM) infections have increased 
worldwide, leading to an emerging public health problem, particularly in industrialized countries, 
sometimes surpassing tuberculosis.11 Among them, M. abscessus represents the most important 
rapidly growing mycobacteria (RGM).12 M. abscessus is indeed responsible for a wide spectrum of 
clinical syndromes ranging from skin infections to severe pulmonary infections in humans with 
compromised natural defenses, such as patients with cystic fibrosis (CF).13-14 The M. abscessus 
complex, along with Mycobacterium avium complex, represents over 90% of all reported NTM-
pulmonary infection cases in CF patients.15-16 Reports also show that M. abscessus isolated from CF 
patients ranged from 16% and up to 68% of all isolated NTM.17-19 In addition, the presence of M. 
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abscessus infection prior to lung transplantation represents a risk factor for developing lung infection 
or a disseminated disease after transplantation.14 M. abscessus displays rough (R) and smooth (S) 
colony morphotypes.20-21 The S morphotype is related to the abundance of the surface-associated 
glycopeptidolipids (GPL), which is associated with sliding motility and biofilm formation.20 In 
contrast, a remarkable reduction in GPL amount in the cell wall of the R variant was correlated with 
cord formation.22 In addition, S and R variants can be considered as two representatives of the same 
isolate, which may coexist and/or evolve differently in response to host immunity, resulting in 
different fates for the mycobacteria in its host.20 Several studies have confirmed the correlation 
between colony morphology and virulence. The S variants are less virulent than R variants,23 which 
are frequently associated with severe pulmonary infections24-25 and are able to persist for years 
especially in infected CF patients.26 In the light of these findings, M. abscessus is known to transition 
from a smooth (S) morphotype with cell surface-associated GPL to a rough (R) morphotype lacking 
GPL. Accordingly, M. abscessus is notorious for being one of the most drug-resistant mycobacterial 
species, refractory to standard antimicrobials used for the treatment of Gram-positive and Gram-
negative bacteria.27 In addition, most antitubercular agents (i.e., rifampin, isoniazid, and ethambutol) 
are also ineffective against M. abscessus, referred to as an “antibiotic nightmare”.28 This intrinsic 
polyresistance to drugs results from multiple factors,29 including the presence of a highly 
impermeable cell envelope preventing the penetration of drug, multiple-drug efflux pumps,30-31 
inability to convert prodrugs into their active metabolites,32 expression of numerous enzymes which 
can modify the drug-target or inactivate the drug itself,27 and the acquisition of mutations in the 
antibiotic targets. Hence, the development of new therapeutic approaches and/or discovery of new 
chemical entities to fight this pathogen are needed.  
Herein, we have synthesized 12 new analogs, i.e. CyC19 to CyC30, by varying the lipophilicity 
of the R3 chain located on the 7-membered enolphosphorus ring in our phosphate and phosphonate 
analogs. This structural modification is also supported by the isolation of the anti-malarial 
Salinipostins,33-34 which are essentially Cyclipostins with variations in the enol alkyl substituent. 
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Their respective antibacterial activity was further assessed against a panel of pathogenic 
mycobacteria, including the M. abscessus R and S variants. Importantly, the MIC of all (26+12) CyCs 
determined against either extracellular or intracellular M. abscessus growth, revealed the efficacy of 
eight new candidates. The potential targets of CyC17 and CyC26, the two most potent inhibitors 
against extracellularly-growing bacteria, were identified via an activity-based protein profiling 
(ABPP) approach.  
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RESULTS AND DISCUSSION 
Synthesis of new Cyclophostin phosphate and phosphonate analogs. We incremented the already 
available library comprising 26 CyC compounds (i.e., CyC1-18 including the cis–() and trans–() 
isomers),7, 10 by synthesizing 12 additional analogs (CyC19-30) from various 3-keto esters following 
previously described synthetic routes (Scheme 1).3-6  
The general approach previously used for the synthesis of phosphonate analogs CyC4-10 was 
applied (Scheme 1A) to the synthesis of cyclic phosphonates with variation in the enol alkyl 
substituent (CyC19-22). The palladium-catalyzed substitution reaction of methyl or ethyl acetoacetate 
derivatives (2)35 with the allylic carbonate (1) gave the vinyl phosphonates (3) as an E/Z mixture in 
good yields (35-63%). The E and Z isomers could be separated by silica gel chromatography, but 
were generally taken into the next reaction as mixture. Quantitative hydrogenation of (3a-d) led to 
the saturated phosphonates (4a-d), which after selective demethylation and cyclization gave the 
racemic forms of monocyclic enolphosphonates (5a-d) corresponding to compounds CyC19 to CyC22 
(17-62%, 2 steps).  
To optimize the potent observed antibacterial activity of compound CyC17,7, 10 the synthesis of 
various monocyclic phosphate analogs has also been completed. Following a literature procedure36-
37 β-ketoesters (8a-d) were prepared by alkylation of t-butyl acetoacetate derivatives (7a-d) with 
iodide (6)38 (Scheme 1B). The tert-butyl ester was chosen so as to minimize the risk of lactonization 
upon deprotection of the alcohol function. Reaction of compounds (8a-d) with dimethyl 
chlorophosphite followed by oxidation of crude material with I2 and methanol gave the 
enolphosphates (9a-d) in modest yield along with recovered starting material (21-49%, 49-81% 
BRSM). The 4-methoxybenzyl ether (PMB) protecting group was then removed with 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) under standard conditions to afford alcohols (10a-d). 
Demethylation and subsequent cyclization using 1-mesitylene-sulfonyl-3-nitrotriazole (MSNT) gave 
the monocyclic phosphate tert-butyl esters CyC27 to CyC30 (11a-d). Cleavage of the tert-butyl moiety 
with TFA in anhydrous conditions followed by TMSCHN2 treatment resulted in the formation of the 
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corresponding racemic cyclic enolphosphate methyl esters CyC23 to CyC26 (12a-d) in good yields 
(79-100%).  
 
Scheme 1. Synthesis of novel monocyclic enol-phosphonate and -phosphate analogs of Cyclophostin. 
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Antibacterial activity of the new CyC19-CyC30 compounds. The antimicrobial activity of the 12 
newly synthesized derivatives was evaluated as previously reported.10 Briefly, a preliminary screen 
on solid medium (30 µM final concentration) was performed on a selected panel of four pathogenic 
mycobacterial species (i.e., M. marinum, M. bovis BCG, M. tuberculosis mc26230, and both S/R 
variants of M. abscessus) and 2 Gram-negative bacteria (Escherichia coli and Pseudomonas 
aeruginosa). Following CFU count, 5 out of the 12 CyCs inhibited growth in the range of 50-100% 
relative to the positive growth control (i.e., bacteria without antibiotics). Moreover, and as previously 
observed with CyC1 to CyC18,10 this inhibitory activity was restricted to the four mycobacteria tested, 
while growth of E. coli and P. aeruginosa was not impacted (see Supplementary Material Table 
S1). The MIC of these selected CyC21, CyC22, CyC25, CyC26 and CyC30 towards each mycobacterial 
strain were next determined using the resazurin microtiter assay (REMA)7, 10 (Table 1). Among the 
abovementioned CyCs, only CyC26 inhibited growth of M. marinum, M. bovis BCG and M. 
tuberculosis, with MIC50 values ranging from 1.8 to 26.4 µM (Table 1). Interestingly, CyC21 and 
CyC22 exhibited the best activity (MIC50 5.6-8.7 μM) against M. tuberculosis mc26230. These latter 
compounds represent two new potential candidates against this bacterium, therefore extending the 
first series of CyC growth inhibitors previously identified.7, 10 
Despite the fact that only CyC25 and CyC26 were active against M. abscessus on solid medium 
(Table 1), we also determined the respective MIC50 values of all CyCs including the first series of 
26 analogs against each S/R variant of M. abscessus to investigate deeper their efficiency/selectivity 
towards this pathogen (see Supplementary Material Table S2). Among the 38 tested compounds 
including the 12 new synthesized analogs, the best growth inhibitors against M. abscessus S variant 
still remained CyC17 and CyC18 which displayed similar MIC50 values (mean MIC50 = 11.7 ±0.94 
µM)10 comparable to that of amikacin (AMK) (Table 1). In all other cases, MIC50 were indicative 
either of a poor (MIC50 ≥117 µM for CyC1-4;6-9;11;16;19;21;27-28), or a moderate (MIC50 = 45-97 µM for 
CyC15;18;20;22;25-26;29-30) antibacterial activity (see Supplementary Material Table S2). By contrast, 
nearly all CyCs were found more active against M. abscessus R variant as compared to the S variant. 
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Although most of the CyCs exhibited quite weak MIC50 in the range 100 to >200 µM; eight analogs 
displayed moderate activities (mean MIC50 = 51.7 ±7.4 µM for CyC6;8;9;18;21-22;29-30) (see 
Supplementary Material Table S2). CyC25 (MIC50 = 13.9 µM) and CyC26 (MIC50 = 6.9 µM) were 
confirmed as very good antimycobacterial molecules, in addition to CyC17 (MIC50 = 0.37 µM) and 
CyC18 (MIC50 = 8.9 µM).
10 Of interest, these latter four best inhibitors of M. abscessus growth were 
all phosphate esters bearing a long lipophilic C10 / C16 alkyl chain either at the R1 or R3 position 
(Figure 1 and Scheme 1).  
 
Table 1. Antibacterial activities of the selected active CyC compounds against four pathogenic 
mycobacterial strains a 
Cpds 
MIC50 (µM) 
M. marinum 
ATCC BAA-535/M 
M. bovis 
BCG 
M. tuberculosis 
mc26230 
M. abscessus 
CIP 104536T 
   S variant R variant 
AMK 1.1 ±0.05 0.54 ±0.03 0.42 ±0.02 3.9 ±0.19 7.4 ±0.26 
INH 20.5 ±0.71 0.71 ±0.03 1.5 ±0.07 >100 >100 
CyC17 
b 1.5 ±0.04 0.54 ±0.01 0.55 ±0.02 12.7 ±0.26 0.37 ±0.01 
CyC18β 
b 23.1 ±1.07 6.0 ±0.29 1.6 ±0.07 10.8 ±0.43 8.9 ±0.09 
CyC21 >100 13.8 ±0.69 8.7 ±0.28 139.0 ±4.80 63.0 ±0.91 
CyC22 >100 24.9 ±1.16 5.6 ±0.25 65.0 ±2.19 51.0 ±2.20 
CyC25 >100 >100 >100 85.0 ±0.86 13.9 ±0.56 
CyC26 1.8 ±0.08 12.4 ±0.44 26.4 ±0.60 60.0 ±2.50 6.9 ±0.16 
CyC30 >100 14.2 ±0.60 >100 62.6 ±2.39 57.0 ±2.70 
a MIC50 corresponding to the concentration leading to 50% growth inhibition as determined by the REMA 
assay, are expressed as mean values of two independent assays performed in triplicate (CV% <5%). b Data for 
CyC17 and CyC18β are from 10. AMK, amikacin. INH, isoniazid. 
 
M. abscessus surface-exposed GPL drives the antibacterial potency of CyC compounds. From 
these results, M. abscessus R appeared to be 6.1- to 34-times more sensitive than M. abscessus S to 
CyC25, CyC26 and CyC17 (Table 1). As previously mentioned, the major difference between these 
two variants resides in the loss of surface-associated glycopeptidolipids (GPL) in the R form.20, 23, 39 
It may be inferred that the GPL covering the surface of M. abscessus S acts as a protective shield 
11 
 
towards the CyCs, although the natural Cyclipostin P CyC18β was not strongly affected by the GPL 
profile. 
To confirm the possible relationship between CyC potency and GPL production, drug 
susceptibility was assessed using the GPL-deficient mmpL4b mutant generated in an S background 
of the type strain CIP104536T, and its complemented counterpart.40-42 The mmpL4b gene encodes for 
the MmpL4b membrane protein, which allows translocation of GPL across the plasma membrane.40, 
43 Mutations in this gene result in the loss of GPLs and acquisition of a R morphotype.23, 40-41 Both 
the wild-type M. abscessus S and the mmpL4b complemented strain responded similarly to CyC17, 
CyC25 and CyC26, with a more pronounced resistance level to these compounds as compared to the 
GPL-deficient mmpL4b mutant, which behaved like the wild-type R variant (Figure 2 and Table 
2). Accordingly and as observed with M. abscessus S vs. R variant, the MIC50 of CyC25, CyC26 and 
CyC17 reached on the mmpL4b complemented strain were 4.8- to 32-times higher than those 
determined on the mmpL4b deletion mutant (Table 2). In contrast, there was a low influence of the 
GPL content in the activity of CyC18β, as judged by the obtained MIC50 values against different strains 
(Table 2).  
 
Table 2. Variation of MIC50 (µM) of CyC17, CyC18β, CyC25 and CyC26 against both R & S variants 
of M. abscessus as well as mmpL4b mutant strains a 
 MIC50 (µM)  Fold change in MIC50 
 
M. abscessus 
S 
M. abscessus 
R 
M. abscessus 
S_mmpL4b 
M. abscessus 
S_mmpL4b::C 
 R → S 
mmpL4b 
→ mmpL4b::C 
CyC17 12.7 ±0.26 0.37 ±0.01 0.60 ±0.03 19.2 ±0.62  ×34.3 ×32.0 
CyC18β 10.8 ±0.43 8.9 ±0.09 3.3 ±0.16 5.4 ±0.26  ×1.2 ×1.6 
CyC25 85.0 ±0.86 13.9 ±0.56 15.7 ±0.73 74.9 ±3.4  ×6.1 ×4.8 
CyC26 60.2 ±2.50 6.9 ±0.16 7.2 ±0.28 67.3 ±3.1  ×8.7 ×9.3 
a MIC50 corresponding to the concentration leading to 50% growth inhibition as determined by the REMA 
assay, are expressed as mean values of two independent assays performed in triplicate (CV% <5%).  
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Figure 2. Dose-response activity of CyC17 and CyC26 against M. abscessus S, mmpL4b mutant (M. abscessus 
S_mmpL4b), mmpL4b complemented (M. abscessus S_mmpL4b::C), and M. abscessus R strains 
replicating in broth medium, expressed as normalized relative fluorescence units (RFU%). For each 
concentration, data are means ± SD of at least two independent assays performed in duplicate (CV% <5%). 
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A significant reduced susceptibility to CyC17 has been reported previously in a M. 
smegmatis_lipg mutant strain in which GPLs were overexpressed due to disruption of lipG, resulting 
in a change vs. WT in MIC50 value of ×15.7 fold.
44 Both results are also in agreement with a study45 
reporting that M. avium GPL-positive serovar was less sensitive to ethambutol than GPL-negative 
one, presumably because hydrophobic GPL may alter cell-wall fluidity/permeability and correlate 
with antibiotic tolerance.45-46 Together, these findings underline the importance of the surface-
exposed GPL in the CyC-dependent inhibition of M. abscessus growth. Remarkably, CyC18β, which 
differs from CyC17 by the presence of a butyrolactone ring fused to the seven-membered cyclic 
phosphate triester (Figure 1), failed to show a high GPL-dependent activity profile. Accordingly, the 
presence of the lactone may be responsible for this behavior, different from the other monocyclic 
CyC analogs, towards M. abscessus variants. 
Activity-based protein profiling (ABPP) approach for targets identification. In light of our 
previous study demonstrating the strong affinity of the CyCs for (Ser/Cys)-enzymes bearing a 
catalytic serine or cysteine residue,4-9, 37, 47-48 we presumed that these inhibitors would also 
target/impair the activity of enzymes participating in a wide range of physiological processes of the 
M. abscessus life cycle, resulting in bacterial growth inhibition, as previously shown in M. 
tuberculosis.7 Hence, to gain access to their putative targets, activity-based protein profiling (ABPP)7, 
49-50 was employed to capture and identify candidate target enzyme(s) impacted by CyC17 and CyC26, 
the two best hits acting against extracellular M. abscessus.  
In the first approach, a crude lysate of M. abscessus R was incubated with either a CyC inhibitor 
(or DMSO as a control) and subjected to a competitive probe labeling/enrichment assay with a 
Desthiobiotin-FP probe (see Supplementary Material Figure S1A).7 The enriched mixtures were 
then digested with trypsin and the resulting peptides analyzed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), followed by subsequent label free quantification analysis. The proteins 
that were also found in the control experiment (i.e., DMSO alone for unspecific binding to 
streptavidin-magnetic beads) were discarded. At first, proteins identified with a permutation false 
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discovery rate (pFDR) up to 10% were selected, leading to a panel of 806 distinct protein candidates 
in the case of CyC17, which was narrowed down to 30 when applying a pFDR of 1%, as compared to 
only 4 with CyC26 (14 at a pFDR of 10%) (see Supplementary Material Tables S3-S8).  
Given the fact that orthologs typically perform equivalent functions in the respective 
organisms,51 the corresponding orthologs in M. tuberculosis H37Rv genome of the various identified 
proteins were reported, adding reliable predictions of the gene functions in terms of essentiality, 
genomic location and activity. With each inhibitor, except for a few uncharacterized proteins, most 
of the identified hits were (Ser/Cys)-based enzymes participating in mycobacterial lipid metabolism 
(see Supplementary Material Tables S4-S5). This was substantiated with CyC26 for which 8 out of 
14 identified proteins are (Ser/Cys)-based enzymes. These included the putative β-lactamase 
MAB_2833 (i.e., Rv1367c), possibly involved in cell wall biosynthesis; the D-amino acid 
aminohydrolase MAB_2605c (i.e., Rv2913c) and the probable peptidase MAB_4130 (i.e., Rv0457c); 
three members of the lipase family Lip, LipH (MAB_2039), LipN (MAB_3270c) and LipW 
(MAB_0826c); and two Cutinase-like proteins, Cut1 (MAB_3272c) and Cut4 (MAB_3809c). 
Interestingly the histidinol-phosphate aminotransferase (i.e., MAB_2669c or HisC1), possibly 
involved in the histidine pathway and annotated as an essential enzyme in M. tuberculosis,52-53 was 
also uncovered with CyC26. All target-proteins of CyC26 were also identified with CyC17, thus 
confirming this latter as a broader multi-target inhibitor. Given the putative mechanism of action of 
HisC1 (MAB_2669c) together with the recent resolution of the 3D structure of its M. tuberculosis 
ortholog Rv1600 in complex with its natural substrate, i.e. pyridoxal-5'-phosphate (PDB id: 4R8D),54 
one can hypothesize that the two phosphate analogs CyC17 and CyC26 may bind to the active site, 
thus acting as substrate-like adducts. 
In the second approach, the penetration/diffusion of CyC17 inhibitor through the mycobacterial 
cell wall was taken into account in order to reduce the list of potential targets. Thus, a similar 
experiment was performed on living bacterial cells.55 M. abscessus R cells were grown to log phase 
and incubated with CyC17 (or DMSO as a control). After cell lysis, part of the lysate was processed 
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as described above with Desthiobiotin-FP probe and streptavidin magnetic beads (see 
Supplementary Material Figure S1B). In parallel, the CyC17-treated lysate was also incubated with 
TAMRA-FP to reveal by in-gel fluorescence on an SDS-PAGE scanning, the (Ser/Cys)-enzyme 
candidates that presumably had reacted with this inhibitor7 (see Supplementary Material Figure 
S1C). At this stage, around 20 distinct bands labeled by TAMRA-FP were detected in the 
fluorescence readout and also visible by Coomassie staining after release of the enzymes captured by 
Desthiobiotin-FP (see Supplementary Material Figure S1C-D). In contrast, pre-treatment with 
CyC17 resulted in a strong decrease in fluorescence intensity of all visible bands; the CyC17-enzyme 
complex being unable to react with the TAMRA-FP probe. Tryptic digestion followed by tandem 
mass spectrometry analysis led to the identification of lower numbers of protein candidates as 
compared to a total lysate; i.e., 39 vs. 208 at a pFDR of 5%, respectively (Supplementary Material 
Table S6). It is noteworthy that among these 39 potential hits, 24 were previously detected in the 
CyC17-treated total lysate (see Supplementary Material Tables S3-4): 16 at a pFDR of 10%, 1 at a 
pFDR of 5%, and 7 at a pFDR of 1%; thus implying that 15 proteins had not been detected in the 
previous treated M. abscessus total lysate, or at least for a pFDR > 10%.  
Consistent with previous work involving CyC17,7 a variety of hydrolases were detected, 
including one amidase AmiC (MAB_2181c), two Lip-family members LipI (MAB_2814) and LipT 
(MAB_3336c), two Cutinase-like proteins Cut1 (MAB_3272c) and Cut3 (MAB_3765), a possible 
hydrolase (MAB_3034), and MAB_176 (Ag85A) and MAB_177 (Ag85-A/B/C precursor) two 
members of the antigen 85 (Ag85) complex, which catalyzes the formation of trehalose dimycolate 
and adds mycolic acids to arabinogalactan9, 56-57 (see Supplementary Material Table S6). 
Interestingly, 9 out of the 39 identified proteins are annotated as essential enzymes in M. tuberculosis 
genome (Table 3).52-53 Among them, MAB_0172 (i.e., Rv3807c) & MAB_3612 (i.e., Rv3265c) are 
possibly involved in the arabinogalactan biosynthesis;58-59 and MAB_0944 (i.e., Rv0896) is a 
probable citrate synthase required for the tricarboxylic acid cycle.60  
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Table 3. CyC17 target proteins identified in M. abscessus R culture by LC-ESI-MS/MS analysis and annotated as essential a for M. tuberculosis orthologs.  
Protein Ids 
Mol. Weight 
[kDa] 
M. tuberculosis orthologs 
Rv number Essentiality Locationb Activity / Function 
Functional 
categoryc 
MAB_0172 19.3 Rv3807c Macrophages M; WCL Putative decaprenylphosphoryl-5-phosphoribose phosphatase CW/CP 
MAB_4481 28.8 Rv0224c essential gene WCL Possible methyltransferase IM/R 
MAB_3612c 32.9 Rv3265c essential gene M; WCL Putative dTDP-rhamnosyltransferase WbbL1 CW/CP 
MAB_1588c 39.0 Rv3230c in vitro growth M; WCL Probable oxidoreductase IM/R 
MAB_4876c 45.0 Rv2017 in vitro growth  Transcriptional regulatory protein RP 
MAB_1524c 46.9 Rv1232c essential gene M; WCL Uncharacterized protein - 
MAB_0944 47.6 Rv0896 in vitro growth CW; M; WCL Probable citrate synthase I GltA2 IM/R 
MAB_3511c 74.8 Rv3198c essential gene WCL Probable ATP-dependent DNA helicase II UvrD2 IP 
MAB_2486c 190.8 Rv3859c in vitro growth CF; CW; WCL Probable gltB, ferredoxin-dependent glutamate synthase IM/R 
a from 52-53. 
b CF: Culture filtrate; CW: Cell wall; M: Membrane fraction; WCL: Whole cell lysate. c IM/R: Intermediary metabolism/respiration; CW/CP: cell wall/cell processes; 
LM: Lipid metabolism; V/D/A: Virulence, detoxification, adaptation. 
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Of particular interest, the Ag85A/B/C proteins from M. tuberculosis have been recently 
validated as real targets of CyC17.7, 9 Herein, we confirm that the recombinant M. abscessus Ag85C 
protein, which shares nearly 60% amino acid sequence identity with its M. tuberculosis ortholog and 
possesses the same conserved catalytic triad (i.e., Ser124-Glu228-His260), is also inactivated by CyC17. 
Ag85CMabs (50 µM) was incubated in its native form with 1 mM (i.e. enzyme/inhibitor molar ratio of 
1:20) CyC17 and then treated with 10 µM TAMRA-FP fluorescent probe for 1 h. Equal amounts of 
proteins (2 µg) were separated by 12% SDS-PAGE and visualized by Coomassie staining or in-gel 
fluorescence for TAMRA detection (see Supplementary Material Figure S2 for details). 
Quantification of labeling normalized to protein load revealed that pre-incubation with CyC17 
resulted in a significant decrease in fluorescence intensity by around 70% as compared with the non-
treated protein. This implies that reaction with the TAMRA probe is strongly impaired in the 
Ag85CMabs-CyC17 adduct, resulting in a significant loss of fluorescence emission. 
Activity of CyC analogs against intracellular M. abscessus. Similar to M. tuberculosis, following 
lung infection M. abscessus can grow and survive intracellularly inside macrophages.13, 20 However, 
MIC values determined in broth medium do not always correlate with the activity of the compounds 
against intracellular bacteria. Such discrepancy between extra- and intracellular activity has been 
reported in the case of M. tuberculosis with the CyCs7 as well as another family of inhibitors, the 
Oxadiazolone-core derivatives.55 From these findings, all 38 CyC analogs were further tested for 
their antibacterial activity against M. abscessus growth inside infected macrophages. 
The cytotoxicity of the 12 new compounds was first assessed using murine Raw264.7 
macrophages.61 Except CyC26 (CC50 = 50 µM), all other inhibitors CyC19-25;27-30 showed very low 
toxicity towards the cells with CC50 > 100 μM, similarly to AMK (CC50 ≥150 μM).62 Taking into 
account our previous toxicity results obtained with CyC1-18,7 the 38 synthesized analogs exhibited 
low cytotoxic towards host mammalian cells.  
Due to its high clumping capability, infection with M. abscessus R results in the lysis of nearly 
all macrophages at 24 h post-infection, making it very difficult to quantify in a reliable manner the 
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intracellular effect of the CyCs. This is, however, not the case with M. abscessus S which does not 
aggregate like the R form, thus enabling the preparation of homogenous and dispersed suspensions. 
The intracellular growth of M. abscessus S was next assessed following a 24 h exposure of infected 
Raw264.7 cells to the CyC compounds at a final concentration of 30 µM.63 To avoid growth of 
extracellular mycobacteria, cells were extensively washed and treated with amikacin (200 µg/mL = 
340 µM; 87 × MIC50) prior to treatment with the CyC analogs. Imipenem (IMP; 80 µg/mL = 267 
µM; 67 × MIC50) was used as positive control for this intracellular killing assay. In each case, the 
viability of infected macrophages was checked by addition of trypan blue64 before cell lysis and 
plating for CFU counting. Nearly all compounds, including the CyC19-30 new series, failed to show 
an effect at the concentration investigated. In agreement with previous work with M. tuberculosis,7 
both (α) and (β) isomers of CyC7 and CyC8, which are not active against extracellular bacilli, showed 
a 40-50% and 63-65% decrease in intramacrophagic CFUs 24 h post infection in the presence of 
CyC7(α,β) and CyC8(α,β), respectively. 
Interestingly, although the phosphate analogs CyC17, CyC18β, CyC25 and CyC26 exclusively 
impaired extracellular growth of M. abscessus, they however remained fully inactive towards infected 
macrophages. In contrast, the phosphonate analogs CyC7-8 were found active only against 
intramacrophagic M. abscessus. Similar properties between the phosphonate (i.e., CyC7-8) vs. 
phosphate (i.e., CyC17) chemical groups have been reported for M. tuberculosis.7 In addition, the fact 
that only CyC7(α,β) and CyC8(α,β) showed a clear preference against intracellularly-replicating 
mycobacteria may imply that the intracellular mode of action of these CyCs differs from that of CyCs 
acting exclusively on extracellularly-replicating bacilli. Another hypothesis is that accessibility 
and/or vulnerability of their corresponding target(s) may be more apparent and crucial during the 
intracellular lifestyle of M. abscessus. Moreover, a specific stringent response of the macrophage, 
such as possible host cell metabolism, stimulated by the action of these latter compounds and leading 
to bacterial clearance cannot, however, be excluded. 
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To confirm this screen, M. abscessus S infected macrophages were subjected to a dose-response 
assay using the latter selected CyC7(α,β) and CyC8(α,β) analogs or IMP (Figure 3), taken as reference 
intracellular drug, in order to determine their respective intracellular MIC50Raw values (Table 4). Both 
CyC7α and CyC7β displayed a moderate activity against intracellular M. abscessus S (Figure 3A) 
with a calculated MIC50Raw of 29.3 µM and 65.3 µM, respectively, similar to that of IMP (MIC50Raw 
= 28.3 µM) used as reference (Table 4). By contrast a 24 h-treatment with either CyC8α or CyC8β led 
to a 68.4 ±6.4% (30-60 µM) and 73.5 ±1.9% (60 µM) reduction in mycobacteria, respectively; which 
was comparable to that elicited by IMP, i.e., 74.0 ±4.4% reduction following treatment with 60 µM 
(Figure 3C). Regarding CyC8β, a plateau value corresponding to 64.7 ±3.8% bacterial killing was 
reached when the infected cells were treated with the compound at a 5-30 µM concentration range. 
Remarkably, MIC50Raw values of CyC8α (7.9 µM) as well as CyC8β (2.0 µM) towards 
intramacrophagic bacilli were 3.6- and 14-fold lower than that of IMP (28.3 µM) (Table 4). These 
MIC50Raw are of the same order of magnitude than those previously obtained with CyC8(α,β) acting 
against intracellular M. tuberculosis (i.e., MIC50Raw_Mtb around 4-12 µM).
7 The selectivity index (SI 
= CC50/MIC50Raw) of the four best inhibitors on intracellular M. abscessus vs. Raw264.7 cells was 
thus found to be in a range from 1.1 and up to 35 for CyC8β. Overall, these results indicate that the 
(α) and (β) isomers of CyC7 and CyC8 could enter the macrophages and arrest bacterial replication 
without exhibiting significant toxicity for the host cell, with comparable effects to IMP.  
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Figure 3. Intracellular activity of (A) CyC7α & CyC7β, and (B) CyC8α & CyC8β as compared to (C) imipenem 
(IMP). The activity of selected CyCs on intracellular M. abscessus was tested in Raw264.7 murine 
macrophages. Cells were infected at a multiplicity of infection (MOI) of 10 with M. abscessus S variant and 
treated with various concentrations of each inhibitor or IMP for 24 h. Then, surviving bacteria were 
enumerated by plating serial dilutions of macrophage lysates. Untreated infected macrophages were used as 
control representing 100% of bacterial viability. Results are shown as mean ± standard error of the mean (SEM) 
of three independent assays performed in triplicate. SC, solvent control (DMSO). **, p-value < 0.01. *, p-
value < 0.05. Statistical analysis was done using a Student’s t-test. 
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Table 4. Antibacterial activities of the most active CyC analogs against M. abscessus S infected 
macrophages a 
Compounds 
CC50 
(µM) 
MIC50Raw 
(µM) 
SI 
IMP ND 28.3 ±4.7 - 
CyC7α >100 29.3 ±2.9 >3.4 
CyC7β >70 65.3 ±6.2 >1.1 
CyC8α >100 7.9 ±0.23 >12.7 
CyC8β >70 2.0 ±0.91 >35 
CyC17 >100 no effect - 
CyC18β >100 no effect - 
CyC25 >100 no effect - 
CyC26 >50 no effect - 
a Experiments were performed as described in Experimental Section. CC50: compound concentration leading 
to 50% Raw264.7 macrophages toxicity. MIC50Raw: minimal compound concentration leading to a 50% 
decrease in CFU count as compared to untreated cells. Raw264.7 macrophages were infected by M. abscessus 
S at a MOI of 10, and further treated with each CyC or IMP for 24 h. The viable mycobacteria were quantified 
using the agar plating method. Untreated infected macrophages were used as control representing 100% of 
bacterial viability. MIC50Raw were calculated from curve fitting of CFU% as a function of the inhibitor 
concentration. Data are expressed as mean values of three independent assays performed in triplicate. IMP, 
imipenem. SI, selectivity index: SI = CC50/MIC50Raw.  
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CONCLUSION 
Herein, we have extended our first series of 26 CyC analogs by synthesizing 12 new 
phosphonate (i.e., CyC19-22) and phosphate (i.e., CyC23-30) compounds in which we varied the R3 
lipophilic chain located on the 7-membered enolphosphorus ring. Evaluation of their antibacterial 
activity first highlighted CyC21 and CyC22 as two potential candidates against M. tuberculosis. With 
respect to M. abscessus, the MIC determination of this set of 38 CyCs provided CyC25 and CyC26, 
in addition to CyC17 and CyC18β, as active inhibitors of R and S variants. We demonstrated that the 
absence of surface-exposed GPL in the R variant was responsible for the higher susceptibility to the 
CyCs as compared to the S strain. The absence of GPL may induce some changes in the cell-wall 
fluidity/permeability, possibly favoring the penetration/action of these inbhibitors. Putative enzymes 
targeted by CyC17 or CyC26, the two best extracellular inhibitors, were identified using an ABPP 
approach. As anticipated, identified proteins were mainly serine or cysteine enzymes involved in 
mycobacterial lipid metabolism, among them 11 were annotated as essential enzymes in M. 
tuberculosis genome for in vitro growth or in infected macrophages. When tested against intracellular 
bacteria, CyC7(α,β) and CyC8(α,β) appeared as very potent and promising inhibitors with comparable 
or even lower MIC50Raw values than that of the standard antibiotics imipenem. Of major interest, such 
inhibitors were selectively and efficiently acting on major pathogenic mycobacteria inside 
macrophages, including M. tuberculosis7 and now also M. abscessus. In addition to their low toxicity 
towards host cells, the CyC inhibitors potentially act as multi-target compounds, confirming their 
potential against one of the most drug-resistant mycobacterial species. It is very likely that blocking 
simultaneously enzymes involved in various lipid and/or in cell wall biosynthetic pathways would 
lead to extracellular and/or intracellular inhibition of M. abscessus growth by the selected CyCs. This 
dual activity of the CyCs is of major importance as it may affect the different stages of the infection 
process. Moreover, their association with current antibiotics to investigate their potential synergetic 
activity against resistant M. abscessus strains is currently in progress, and could open the way for 
improving the current treatments against these mycobacterial infections.   
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EXPERIMENTAL SECTION 
Chemistry - synthesis of compounds CyC19 to CyC30 
The synthesis of natural Cyclophostin CyC1,4 its phosphonate analogs CyC2 and CyC2,3 the 
monocyclic enolphosphonates CyC3-447 and the trans-() and cis-() diastereoisomers CyC5-10;5 as 
well as the trans-() and cis-() Cyclipostin P CyC184 and the corresponding monocyclic 
phosphonate CyC11-13,5, 7 difluorophosphonate CyC14-15 and phosphate CyC16-176, 37 analogs have 
already been reported. The 12 new analogs (CyC19-30) where synthesized in racemic form from 
various 3-keto esters following already described synthetic routes (See Supplementary Material for 
detailed procedures and the full chemical characterization of each new compounds),3-6 and have 
purity of ≥ 95% as determined by HPLC analysis as reported previously.5 The HPLC data were 
supported by careful analysis of the 1H, 13C and particularly the 31P NMR spectra (see 
Supplementary Material). Stock solutions (10 mM) in which the CyC compounds were found to 
be completely soluble in dimethyl sulfoxide (DMSO), were prepared prior to drug susceptibility 
testing.  
Antibacterial evaluation.  
Bacterial strains and growth condition. M. marinum ATCC BAA-535/M, M. bovis BCG 
Pasteur, M. abscessus CIP104536T with either a smooth (S) or rough (R) morphotype, and M. 
tuberculosis mc26230 (H37Rv RD1 panCD65) strains were routinely grown in Middlebrook 7H9 
broth (BD Difco, Le Pont de Claix, France) supplemented with 0.2% glycerol, 0.05% Tween 80 
(Sigma-Aldrich, St. Quentin Fallavier, France) and 10% oleic acid, albumin, dextrose, catalase 
(OADC enrichment; BD Difco) (7H9-S). In the case of M. tuberculosis mc26230, 24 µg/mL D-
pantothenate (Sigma-Aldrich) was also added in the 7H9-S medium. All cultures were kept at 37 °C 
without shaking, except M. marinum which was grown at 32 °C. Escherichia coli DH10B and 
Pseudomonas aeruginosa PA01 were grown at 37 °C in LB Broth Base medium (ThermoFisher 
Scientific, Illkirch, France). A M. abscessus S mmpL4b KO (M. abscessus S_mmpL4b) mutant 
displaying an R morphotype40 and its complemented counterpart (M. abscessus S_mmpL4b::C), 
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which stably expresses MmpL4b under the control of the hsp60 promoter, were also used as 
previously reported in20.  
Antibiotics. Amikacin was purchased from Euromedex (Souffelweyersheim, France), and 
imipenem was provided by Mylan (Saint-Priest, France). Stock solution in water were freshly 
prepared for each experiment and filtered through a sterilized 0.22-µm-pore-size polycarbonate 
syringe filter (Millipore, Saint-Quentin-en-Yvelines, France). 
Drug susceptibility testing on solid medium. This was performed in 24-well suspension culture 
plates (Greiner bio-one) as described previously.66 E. coli and P. aeruginosa were grown on LB agar 
medium at 37 °C. All mycobacteria were grown at either 32 °C (M. marinum) or 37 °C (M. abscessus, 
M. bovis BCG and M. tuberculosis mc26230) on Middlebrook 7H10 agar (BD Difco) supplemented 
with 10% OADC, and 24 µg/mL D-pantothenate (M. tuberculosis mc26230). The wells were filled 
with 1 mL of the appropriate medium containing each of the CyC19-CyC30 analogs at a single 30 µM 
final concentration. Each screening plate contained negative (DMSO) and positive (50 μM 
antibiotics) controls, as well as one well for sterility control (i.e., medium alone). For the 100% 
inhibition control we used 50 µM amikacin (Sigma Aldrich) for M. marinum, M. abscessus, M. bovis 
BCG, M. tuberculosis mc26230 and E. coli; and 50 µM carbenicillin (Sigma Aldrich) for P. 
aeruginosa. Each well was spotted with 10 µL of a bacterial culture at 5 × 105 cells/mL. Colonies 
were counted after 1 day to 2 weeks of incubation at 37 °C, depending on the strain tested, to check 
bacterial viability. The CyC compounds leading to a minimum of 50% growth inhibition from CFU 
count were selected for subsequent MIC determination using the REMA assay.  
Resazurin microtiter assay (REMA) for MIC determination. The concentrations of compound 
leading to bacterial growth inhibition were first determined using the resazurin microtiter assay 
(REMA).7, 10, 55 Briefly, log-phase bacteria were diluted to a cell density of 5 × 106 cells/mL and 100 
µL of this inoculum was grown in a 96-well plate in the presence of serial dilutions of compounds. 
After 7-14 days incubation, 20 µL of a 0.025% (w/v) resazurin solution was added to each well (200 
µL) and incubation was continued until the appearance of a color change (from blue to pink) in the 
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control well (bacteria without antibiotics). Fluorescence of the resazurin metabolite resorufin 
(excitation, 530 nm; emission, 590 nm) was then measured,7, 10, 55 and the concentration leading to 50% 
growth inhibition was defined as the MIC50. See Supplementary Material for detailed protocol. 
Determination of cytotoxic activity for new CyC19-CyC30 analogs (resazurin assay). The 
cytotoxicity of compounds against eukaryotic cells was measured based on the reduction of 
resazurin61, 63 as a value of cellular viability by metabolic activity. Murine (Raw264.7) macrophages 
(American Type Culture Collection TIB-71) were cultured from a freezer stock in Dulbecco’s 
modified Eagle medium (DMEM; Gibco) supplemented with 10% heat-inactivated fetal calf serum 
(FBS, Invitrogen) (DMEMFBS). Cells were grown at 37 °C and 5% CO2 to subconfluent 
concentrations, then 1 × 105 cells/well were seeded in 96-well flat-bottom Nunclon Delta Surface 
microplates with lid (ThermoFisher Scientific, ref. 167008) in a final volume of 200 µL per well and 
cultured for additional 24 h. The medium was removed by aspiration, and 200 µL of serial two-fold 
dilution of each compound (CyC19 to CyC30) in DMEMFBS were then added to each well. After 24 h 
incubation, 20 µL of a 0.025% (w/v) resazurin solution was added to each well. Fluorescence was 
measured following a 4-h incubation at 37 °C and 5% CO2 in the dark, by excitation at 530 nm and 
emission at 590 nm as described above, leading to relative metabolic activities. Addition of DMSO 
was used as 100% viability reference and addition of 0.2% Triton X-100 solution served as negative 
standard (0% viability). All experiments were performed as two independent triplicates. 
Intramacrophage killing assay. Murine (Raw264.7) macrophages (American Type Culture 
Collection TIB-71) were grown in DMEMFBS medium at 37 °C and 5% CO2 to subconfluent 
concentrations, then 5 × 104 cells/well were seeded in 96-well flat-bottom Nunclon Delta Surface 
microplates with lid (ThermoFisher Scientific, ref. 167008) in a final volume of 200 µL per well and 
cultured for additional 24 h. The cells were infected with M. abscessus S at a multiplicity of infection 
(MOI) of 1:10 and incubated at 37 °C in the presence of 5% CO2 for 3 h. Cells were then washed 
three times with DMEM then refed with DMEMFBS supplemented with 200 μg/mL amikacin for 1 h. 
at 37 °C and 5% CO2 to kill all extra-cellular bacteria; washed again three times with DMEM prior 
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to the addition of 2-fold dilutions of CyC compounds or imipenem (IMP) in DMEMFBS supplemented 
with 50 µg/mL (i.e., 85.4 µM) amikacin (200 µL final volume). In each plate, negative controls 
consisting of amikacin (50 µg/mL) and 1% DMSO (i.e., infected macrophages only); as well as 
positive controls containing amikacin (50 µg/mL) plus 80 μg/mL (i.e., 267 µM) IMP were also 
included. Plates were incubated for 24 h at 37 °C, 5% CO2. Cells were washed three times with PBS 
and lysed by adding 200 μL of 0.1% Triton X-100. Serial dilutions of each culture were then plated 
at least in duplicate on 7H9 agar medium. Colonies were counted after 4 to 5 days of incubation at 
37 °C to check intracellular bacterial viability following treatment with each compound 
concentration. DMSO-treated infected macrophages corresponded as control representing 100% of 
bacterial viability. Intracellular MICRaw values were determined by fitting the CFU% sigmoidal dose-
response curves in Kaleidagraph 4.2 software (Synergy Software). The lowest compound 
concentration inhibiting 50% of intracellular bacterial growth was defined as the MIC50Raw. 
Experiments were done three times independently.  
CyC17 and CyC26 target enzymes identification.  
Activity-based protein profiling (ABPP). Homogeneous bacterial suspension of M. abscessus 
R in 7H9-S was adjusted at an OD600 of 40 and then incubated with the selected CyC17 or CyC26 
inhibitor (400 µM final concentration) or DMSO (control) at 37 °C for 2-3 h. under gentle shaking at 
75 rpm. Bacteria were then washed 3 times with PBS containing 0.05% Tween 80, resuspended in 
PBS buffer at a 1:1 (w/v) ratio and then lysed by mechanical disruption on a BioSpec Beadbeater. 
Both CyC-treated M. abscessus and DMSO-control lysate samples (750 µL – 0.75 mg total proteins) 
were labeled with 2 µM Desthiobiotin-FP probe for 90 min at room temperature. Samples were 
enriched for biotinylated proteins using Nanolink streptavidin magnetic beads 0.8 µm (Solulink), 
according to the manufacturer’s instructions. The resulting captured biotinylated proteins solution 
was mixed with 5X Laemmli reducing sample buffer, and heated at 95 °C for 5 min. The released 
denatured proteins were subjected to tryptic digestion, peptide extraction, and LC-MS/MS analysis 
as described below. Alternatively, the CyC-treated M. abscessus and DMSO-control lysate samples 
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(100 µL – 100 µg total proteins) were incubated with 2 μM ActivX TAMRA-FP probe (Thermo 
Fisher Scientific) for 90 min at room temperature and in absence of light. The reaction was stopped 
by adding 4X Laemmli reducing sample buffer and boiling at 95 °C for 5 min. The labeled proteins 
were further separated by SDS-PAGE electrophoresis. TAMRA fluorescence (TAMRA: λex 557 nm, 
λem 583 nm) was detected using a ChemiDoc MP Imager (Bio-Rad).  
Detailed Material and Methods regarding ABPP experiments is given in Supplementary Material. 
Protein identification and quantification. Protein extract were loaded and stacked on a 
NuPAGE gel (Life Technologies). Stained bands were submitted to an in-gel trypsin digestion.67 
Peptides extracts were reconstituted with 0.1% trifluoroacetic acid in 4% acetonitrile and analyzed 
by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) using a LTQ-Orbitrap Velos 
Mass Spectrometer (Thermo Electron, Bremen, Germany) online with a nanoLC Ultimate 3000 
chromatography system (Dionex, Sunnyvale, CA). Protein identification and quantification were 
processed using the MaxQuant computational proteomics platform, version 1.5.3.868 using a UniProt 
M. abscessus ATCC 19977 (Taxon 561007) database (date 2018.01; 4940 entries). The statistical 
analysis was done with Perseus program (version 1.5.6.0). Differential proteins were detected using 
a two-sample t-test at 0.01 and 0.05 permutation based FDR. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium (www.proteomexchange.org)69 via the 
PRIDE partner repository with the dataset identifier PXD014255.  
Detailed Material and Methods is given in Supplementary Materials. 
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S2 (Extracellular antibacterial activities of all CyC analogs against both R & S variants of M. 
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